The Association Between Psoriasis and Intestinal Bacterial Population (PIB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02417792|
Recruitment Status : Completed
First Posted : April 16, 2015
Last Update Posted : September 25, 2019
|Condition or disease|
Intestinal bacterial population has a significant influence on health and sickness conditions. It affects the development and the function of the immune system (Th2, Th1 or Th17) by bacterial protein expression and by the composition of the bacterial population.
Psoriasis is an immune related dermal disease. The trigger for this disease is currently unknown but, it is possible that intestinal bacteria are a factor in its development.
Participants will be divided into 3 groups:
- Psoriasis patients treated with topical medications
- Psoriasis patients treated with IV or sub-cutaneous medications (e.g biological medications)
- Healthy participants (control group) Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.
|Study Type :||Observational|
|Actual Enrollment :||46 participants|
|Official Title:||The Association Between Psoriasis and Intestinal Bacterial Population|
|Actual Study Start Date :||May 14, 2015|
|Actual Primary Completion Date :||January 6, 2019|
|Actual Study Completion Date :||February 18, 2019|
group of healthy participants
Topical psoriasis treatment
Group of patients who are treated with topical medications for psoriasis
Systemic psoriasis treatment
Group of patients who are treated with systematic medications for psoriasis
- A significant change (P<0.05) in enteric bacterial composition of psoriasis patients (n=20) vs controls (n=20) as assessed by alpha diversity, beta diversity and taxonomic analysis. [ Time Frame: 2 years ]To examine whether fecal bacterial populations of psoriasis patients (not treated by enteral medications) are different compared to healthy participants
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02417792
|Principal Investigator:||Jonathan Shapiro, Dr.||Maccabi Healthcare Services, Israel|